Janux Therapeutics, Inc. $JANX Shares Purchased by Readystate Asset Management LP

Readystate Asset Management LP boosted its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 38.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 960,379 shares of the company’s stock after purchasing an additional 264,423 shares during the period. Janux Therapeutics makes up 1.0% of Readystate Asset Management LP’s holdings, making the stock its 23rd biggest holding. Readystate Asset Management LP’s holdings in Janux Therapeutics were worth $23,472,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of JANX. Osaic Holdings Inc. increased its holdings in shares of Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares during the last quarter. Virtus Investment Advisers LLC grew its position in Janux Therapeutics by 37.9% in the second quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after acquiring an additional 1,011 shares during the period. Tower Research Capital LLC TRC increased its stake in Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after acquiring an additional 2,502 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in Janux Therapeutics by 25.6% in the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after purchasing an additional 820 shares during the period. Finally, FNY Investment Advisers LLC raised its position in Janux Therapeutics by 111.8% in the second quarter. FNY Investment Advisers LLC now owns 5,210 shares of the company’s stock valued at $120,000 after purchasing an additional 2,750 shares during the period. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on JANX shares. UBS Group reissued a “buy” rating and set a $57.00 price objective on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Wolfe Research initiated coverage on shares of Janux Therapeutics in a research note on Tuesday, November 18th. They set a “peer perform” rating for the company. Wall Street Zen raised shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a report on Thursday, January 22nd. Finally, Barclays lowered their price objective on shares of Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. Eleven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $60.08.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock opened at $13.21 on Wednesday. The business has a 50-day simple moving average of $13.93 and a 200-day simple moving average of $21.27. Janux Therapeutics, Inc. has a one year low of $12.12 and a one year high of $38.42. The company has a market cap of $794.58 million, a PE ratio of -7.86 and a beta of 2.88.

Insider Activity

In other Janux Therapeutics news, insider Charles M. Winter sold 2,401 shares of Janux Therapeutics stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $32,965.73. Following the completion of the sale, the insider directly owned 77,721 shares of the company’s stock, valued at $1,067,109.33. The trade was a 3.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Andrew Hollman Meyer sold 3,333 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $32.98, for a total value of $109,922.34. Following the transaction, the insider directly owned 84,974 shares of the company’s stock, valued at approximately $2,802,442.52. This represents a 3.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 22,366 shares of company stock valued at $371,245. Insiders own 29.40% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.